Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jed Bartschi

Physician Assistant, Medical Idaho Falls, ID Physician Assistant

NPI 1083793699 CMS profile 11136379

1957 E 17Th St, Idaho Falls, ID 83404

Open in the dashboard

General payments

$10,548

592 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jed Bartschi of Idaho Falls, ID is reported in the CMS Open Payments database as having received $10,548 across 592 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,471 118
2024 General $2,051 114
2023 General $2,296 139
2022 General $1,922 117
2021 General $1,807 104

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jed Bartschi
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jed Bartschi were reported at $2,471. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jed Bartschi Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,807 $156 $41–$563 $132
2022 $1,922 $185 $55–$649 $149
2023 $2,296 $199 $58–$717 $160
2024 $2,051 $206 $62–$740 $164
2025 $2,471 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Pfizer Inc. $856 75 payments
  2. AstraZeneca Pharmaceuticals LP $813 40 payments
  3. Novartis Pharmaceuticals Corporation $648 43 payments
  4. AbbVie, Inc. $414 21 payments
  5. Merck Sharp & Dohme Corporation $397 21 payments
  6. Daiichi Sankyo Inc. $394 19 payments
  7. Genentech USA, Inc. $389 25 payments
  8. Incyte Corporation $387 18 payments
  9. E.R. Squibb & Sons, L.L.C. $378 25 payments
  10. Astellas Pharma US Inc $369 16 payments
  11. Other $5,503 289 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,101 586 payments
  2. Education $447 6 payments
Products named General payments · program years 2021–2025
  1. IMBRUVICA $439 19 payments
  2. KEYTRUDA $397 21 payments
  3. OPDIVO $370 24 payments
  4. Lenvima $352 19 payments
  5. XTANDI $344 27 payments
  6. BOSULIF $322 24 payments
  7. IMFINZI $322 13 payments
  8. VERZENIO $281 15 payments
  9. KISQALI $270 16 payments
  10. ENHERTU $246 11 payments
  11. Other $9,558 609 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

526

Median for Physician Assistant: 241

Drug cost

$500,327

Median for Physician Assistant: $4,110

Branded share of claims

21.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 12 $167,555
Promacta Eltrombopag Olamine Brand 11 $156,978
Xermelo Telotristat Etiprate Brand 20 $140,834
Eliquis Apixaban Brand 26 $23,006
Ondansetron Hcl Generic 50 $6,099
Tamoxifen Citrate Generic 43 $1,448
Potassium Chloride Generic 27 $790
Anastrozole Generic 34 $711
Gabapentin Generic 24 $581
Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine Brand 21 $416

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$27,184

Medicare's payments for the services billed

Medicare patients

169

Average age 73

Services billed

377

105 women, 64 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Cancer 49%
Arthritis 49%
Diabetes 30%
Chronic kidney disease 22%
Depression 20%
Osteoporosis 20%
Ischemic heart disease 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 60 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Lenvima
  • Eisai Inc. $131
$131 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $89
$89 — —
IMFINZI
  • AstraZeneca Pharmaceuticals LP $87
$87 — —
NINLARO
  • Takeda Pharmaceuticals U.S.A., Inc. $78
$78 — —
Zoladex
  • TerSera Therapeutics LLC $76
$76 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 60 with Patron

Records

592 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record